The Title of the Video Would Go Here

Press Release:

SynCardia Systems Appoints Rodger G. Ford to Board of Directors

Entrepreneur and Business Leader to Provide Strategic Counsel on the Continued Development and Marketing
of the CardioWest™ temporary Total Artificial Heart

TUCSON, Ariz. – May 11, 2004 – SynCardia Systems, Inc., a privately held developer of biomechanical cardiac replacement and assist devices, announced today the appointment of Rodger G. Ford to its Board of Directors.

Mr. Ford brings more than 30 years of entrepreneurial accomplishments and leadership to the SynCardia Board, having founded AlphaGraphics Print Shops of the Future and Anthem Equity Group, Inc. Under Mr. Ford’s leadership, AlphaGraphics grew to more than 400 locations worldwide, with franchises in Canada, South America, Australia, Europe and the Middle East. At Anthem Equity Group, which develops and operates office and industrial real estate, Mr. Ford in responsible for new business opportunities and venture investing. Mr. Ford has served on Boards for numerous organizations and was named Ernst & Young Entrepreneur of the Year in 2000.

“Rodger’s leadership, vision and experience in growing successful companies makes him an invaluable resource for SynCardia. This is exciting time for SynCardia as the CardioWest™ temporary Total Artificial Heart continues on course to become the world’s first FDA-approved total artificial heart,” said Dr. Marvin Slepian, president and CEO, SynCardia. “We look forward to his strategic counsel as SynCardia moves into the next state of corporate growth both in the United States and in Europe, where the CardioWest™ TAH-t is already available.”

“The market potential for the CardioWest™ temporary Total Artificial Heart is tremendous and I am pleased to provide SynCardia’s Board of Directors and executive team with guidance and support at this exciting juncture,” said Rodger Ford.


About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end stage heart failure affecting both sides of the heart (biventricular failure). There have been nearly 1,300 implants of the Total Artificial Heart, accounting for more than 350 patient years of life on the device.

Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It is the only device that eliminates the symptoms and source of end stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at 97 SynCardia Certified Centers worldwide with 39 others in the process of certification.

The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

For up-to-date information, please visit:
Like SynCardia on Facebook
Follow SynCardia on Twitter – @SynCardia
Connect with SynCardia on LinkedIn


Media Contact:
Don Isaacs
Vice President of Communications
SynCardia Systems, Inc.
Cell: (520) 955-0660



*The SynCardia temporary Total Artificial Heart was formerly known as the
SynCardia temporary CardioWest™ Total Artificial Heart.

FREE News Sign-Up

3538727_sBe Among the First to
Receive SynCardia News

... right in your email box